MMMiriam P. van der Meulen

Miriam P. van der Meulen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miriam P. van der Meulen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Ernst J. Kuipers

    From the Departments of Public Health (M.P.v.d.M., I.L.V., S.L.G., M.v.B.), Gastroenterology and Hepatology (E.J.K.), and Internal Medicine (E.J.K.), Erasmus Medical Centre, University Medical Center Rotterdam, PO Box 2040, 3000 CA Rotterdam, the Netherlands; Department of Gastroenterology and Hepatology (E.D.) and Department of Radiology (J.S.), Academic Medical Center, Amsterdam, the Netherlands

    3 shared publications
  • Iris Lansdorp-Vogelaar

    Department of Public Health, Erasmus Medical Centre, Rotterdam, the Netherlands

    3 shared publications
  • Iris Lansdorp-Vogelaar

    Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands

    3 shared publications
  • Esther Toes-Zoutendijk

    Department of Public Health, Erasmus MC University Medical Center, Rotterdam, The Netherlands

    2 shared publications
  • Evelien Dekker

    Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands

    2 shared publications
  • Harry J. de Koning

    Department of Public Health, Erasmus Medical Centre, Rotterdam, the Netherlands

    2 shared publications

Latest Publications

  • Open Access

    Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy – a nationwide survey

    by Miriam P. van der Meulen, Ida J. Korfage, Else-Mariëtte B. van Heijningen, Harry J. de Koning, Monique E. van Leerdam, Evelien Dekker, Iris Lansdorp-Vogelaar, on behalf of the working group on the guideline for colonoscopy surveillance

    Background and study aims Low adherence to the Dutch guideline for colonoscopy surveillance after polypectomy led to release of a new guideline in 2013. This new guideline was risk-stratified at a more detailed level than the previous one to achieve more efficient use of colonoscopy resources. This study assessed the feasibility of the risk-stratified guideline by evaluating correct interpretation of and adherence to this guideline. Methods Based on semi-structured interviews with 10 gastroenterologists, we developed an online survey to evaluate gastroenterologists’ recommendations for surveillance in 15 example cases of patients with polyps. If recommended intervals differed from the new guideline, respondents were asked to indicate their motives for doing so. Results Ninety-one of 592 (15.4 %) invited gastroenterologists responded to at least one case, of whom 84 (14.2 %) completed the survey. Gastroenterologists gave a correct recommendation in a median of 10 of 15 cases and adherence per case ranged from 14 % to 95 % (median case 76 %). The two cases that addressed management of serrated polyps were least often answered correctly (14 % and 28 % correct answers). Discrepancies were mainly due to misinterpretation of the guideline with respect to serrated polyps (48 %) or misreading of the questions (30 %). Conclusions Median adherence to the updated colonoscopy surveillance guideline of 76 % seems reasonable, and is higher than adherence to the previous guideline (range: 22 %-80 %, median 59 %). This shows that detailed (more complex) risk stratification for designation of a surveillance interval is feasible. Adherence could potentially be improved by clarifying correct interpretation of serrated polyps. Received: 14 July 2019 Accepted: 24 April 2020 Publication Date: 22 September 2020 (online) © 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany


  • Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs

    by Miriam P. van der Meulen, Iris Lansdorp-Vogelaar, S. Lucas Goede, Ernst J. Kuipers, Evelien Dekker, Jaap Stoker, Marjolein van Ballegooijen

    On the basis of randomized controlled screening trial data showing higher participation rates for CT colonography, CT colonography is more cost-effective than colonoscopy screening for colorectal c... PurposeTo compare the cost-effectiveness of computed tomographic (CT) colonography and colonoscopy screening by using data on unit costs and participation rates from a randomized controlled screeni...


  • Open Access

    Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model

    by Arantzazu Arrospide, Isabel Idigoras, Javier Mar, Harry de Koning, Miriam van der Meulen, Myriam Soto-Gordoa, Jose Miguel Martinez-Llorente, Isabel Portillo, Eunate Arana-Arri, Oliver Ibarrondo, et al.

    The Basque Colorectal Cancer Screening Programme began in 2009 and the implementation has been complete since 2013. Faecal immunological testing was used for screening in individuals between 50 and 69 years old. Colorectal Cancer in Basque country is characterized by unusual epidemiological features given that Colorectal Cancer incidence is similar to other European countries while adenoma prevalence is higher. The object of our study was to economically evaluate the programme via cost-effectiveness and budget impact analyses with microsimulation models. We applied the Microsimulation Screening Analysis (MISCAN)-Colon model to predict trends in Colorectal Cancer incidence and mortality and to quantify the short- and long-term effects and costs of the Basque Colorectal Cancer Screening Programme. The model was calibrated to the Basque demographics in 2008 and age-specific Colorectal Cancer incidence data in the Basque Cancer Registry from 2005 to 2008 before the screening begun. The model was also calibrated to the high adenoma prevalence observed for the Basque population in a previously published study. The multi-cohort approach used in the model included all the cohorts in the programme during 30 years of implementation, with lifetime follow-up. Unit costs were obtained from the Basque Health Service and both cost-effectiveness analysis and budget impact analysis were carried out. The goodness-of-fit of the model adaptation to observed programme data was evidence of validation. In the cost-effectiveness analysis, the savings from treatment were larger than the added costs due to screening. Thus, the Basque programme was dominant compared to no screening, as life expectancy increased by 29.3 days per person. The savings in the budget analysis appeared 10 years after the complete implementation of the programme. The average annual budget was €73.4 million from year 2023 onwards. This economic evaluation showed a screening intervention with a major health gain that also produced net savings when a long follow-up was used to capture the late economic benefit. The number of colonoscopies required was high but remain within the capacity of the Basque Health Service. So far in Europe, no other population Colorectal Cancer screening programme has been evaluated by budget impact analysis.


  • Open Access

    Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis

    by Miriam P. van der Meulen, Atija Kapidzic, Monique E. van Leerdam, Alex van der Steen, Ernst J. Kuipers, Manon C.W. Spaander, Harry J. de Koning, Lieke Hol, Iris Lansdorp-Vogelaar

    Background: Several studies suggest that test characteristics for the fecal immunochemical test (FIT) differ by gender, triggering a debate on whether men and women should be screened differently. We used the microsimulation model MISCAN-Colon to evaluate whether screening stratified by gender is cost-effective. Methods: We estimated gender-specific FIT characteristics based on first-round positivity and detection rates observed in a FIT screening pilot (CORERO-1). Subsequently, we used the model to estimate harms, benefits, and costs of 480 gender-specific FIT screening strategies and compared them with uniform screening. Results: Biennial FIT screening from ages 50 to 75 was less effective in women than men [35.7 vs. 49.0 quality-adjusted life years (QALY) gained, respectively] at higher costs (€42,161 vs. −€5,471, respectively). However, the incremental QALYs gained and costs of annual screening compared with biennial screening were more similar for both genders (8.7 QALYs gained and €26,394 for women vs. 6.7 QALYs gained and €20,863 for men). Considering all evaluated screening strategies, optimal gender-based screening yielded at most 7% more QALYs gained than optimal uniform screening and even resulted in equal costs and QALYs gained from a willingness-to-pay threshold of €1,300. Conclusions: FIT screening is less effective in women, but the incremental cost-effectiveness is similar in men and women. Consequently, screening stratified by gender is not more cost-effective than uniform FIT screening. Impact: Our conclusions support the current policy of uniform FIT screening. Cancer Epidemiol Biomarkers Prev; 26(8); 1328–36. ©2017 AACR.


  • Open Access

    Nonbleeding adenomas: Evidence of systematic false‐negative fecal immunochemical test results and their implications for screening effectiveness—A modeling study

    by Miriam P. van der Meulen, Iris Lansdorp‐Vogelaar, Else‐Mariëtte B. van Heijningen, Ernst J. Kuipers, Marjolein van Ballegooijen

    BACKGROUND: If some adenomas do not bleed over several years, they will cause systematic false‐negative fecal immunochemical test (FIT) results. The long‐term effectiveness of FIT screening has been estimated without accounting for such systematic false‐negativity. There are now data with which to evaluate this issue.METHODS: The authors developed one microsimulation model (MISCAN [MIcrosimulation SCreening ANalysis]‐Colon) without systematic false‐negative FIT results and one model that allowed a percentage of adenomas to be systematically missed in successive FIT screening rounds. Both variants were adjusted to reproduce the first‐round findings of the Dutch CORERO FIT screening trial. The authors then compared simulated detection rates in the second screening round with those observed, and adjusted the simulated percentage of systematically missed adenomas to those data. Finally, the authors calculated the impact of systematic false‐negative FIT results on the effectiveness of repeated FIT screening.RESULTS: The model without systematic false‐negativity simulated higher detection rates in the second screening round than observed. These observed rates could be reproduced when assuming that FIT systematically missed 26% of advanced and 73% of nonadvanced adenomas. To reduce the false‐positive rate in the second round to the observed level, the authors also had to assume that 30% of false‐positive findings were systematically false‐positive. Systematic false‐negative FIT testing limits the long‐term reduction of biennial FIT screening in the incidence of colorectal cancer (35.6% vs 40.9%) and its mortality (55.2% vs 59.0%) in participants.CONCLUSIONS: The results of the current study provide convincing evidence based on the combination of real‐life and modeling data that a percentage of adenomas are systematically missed by repeat FIT screening. This impairs the efficacy of FIT screening. Cancer 2016;122:1680‐8. © 2016 American Cancer Society.


  • Sa1219 Impact of Mortality From Surgical Adenoma Removal on the Effectiveness of Colorectal Cancer Screening

    by Maaike Buskermolen, Miriam P. van der Meulen, Esther Toes-Zoutendijk, Monique van Leerdam, Manon Spaander, Harry de Koning, Iris Lansdorp-Vogelaar

  • Mo1706 Optimizing Screening Programs by Real-Time Monitoring: Outcomes of the National Colorectal Cancer FIT-Based Screening Program of the Netherlands

    by Esther Toes-Zoutendijk, Monique van Leerdam, Evelien Dekker, Frank van Hees, Folkert van Kemenade, Miriam P. van der Meulen, Anneke van Vuuren, Ernst J. Kuipers, Johannes M.G. Bonfrer, Katharina Biermann, et al.